Galunisertib (LY2157299) Mechanism of Action: TGF-βRI Inhibition in Tumor Cell Research

Galunisertib (LY2157299) MOA:Targeting TGF-βRI/SMAD2 Pathway for Oncology

🎯 check Galunisertib (LY2157299) product page

Galunisertib is a specific small-molecule TGF-βR1 inhibitor. By blocking TGF-βR1 kinase activity and inhibiting SMAD2/3 phosphorylation, it suppresses the TGF-β/Smad signaling pathway, thereby inhibiting EMT, cell migration, and fibrosis.

Primary Applications and Mechanism of Action